HDL Target of CoViD19 ? Analysis on the Caregivers of the Reunion University Hospital

NCT04384705 | Unknown

• 1 other identifier: 2020/CHU/08
• Study Type: observational
• Target: 361
• Locations: 1 country
• Sites: 2

Brief Summary

Since December 2019, the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) pandemic has spread around the world. The people most exposed to this virus remain the healthcare personnel who are on the front line in the fight against this pandemic. Due to the delayed nature of the pandemic in Reunion island and its insular geographical situation, the study of the voluntary medical personnel will allow the investigators to establish a longitudinal follow-up of the anomalies of the lipidic balance in relation to the exposure to the SARS-Cov virus. 2. During bacterial infections, the lipid profiles are profoundly modified with very significant reductions in plasma cholesterol levels, LDL-C but especially HDL-C whose concentrations are particularly low. Lipid profiles are altered during viral infections, for example, the severity of dengue is inversely correlated with total cholesterol and LDL-C but not with HDL-C levels, according to a recent meta-analysis. The hepatitis C virus circulates in serum linked to lipoproteins rich in triglycerides and HDL can facilitate its entry into cells via Scavenger receptor class B type 1 (SRB1). Likewise, it has been shown that apoA1 can bind to the dengue virus and increase its infectivity by promoting its entry into cells, also via SRB1. At the moment, nothing is known about the lipid profiles in subjects with SARS-CoV-2. The investigator hypothesize that a drop in plasma HDL-C levels and a change in their size during infection could justify future therapeutic approaches aimed at supplementing the subjects most at risk of pulmonary complications. In a model of Pseudomonas aeruginosa pneumonia in mice, investigators have shown that the injection of reconstituted HDL allowed to limit the pulmonary inflammation and the deleterious consequences of the infection. The investigator propose to study not only the lipid profiles in subjects who are infected with SARS-CoV-2 but also the polymorphisms of genes involved in the regulation of lipoprotein levels like that of Cholesterol Ester-Transfer Protein (CETP) depending on the developed forms, symptomatic or not.

Conditions

SARS-CoV Infection

Outcome Measures

Primary Outcomes (1)

• Change of lipid profile during exposure to SARS-Cov-2

  lipid profile

  at the end of the study, maximum 1 year

Secondary Outcomes (3)

• HDL-cholesterol size

  at the end of the study, maximum 1 year

• circulating plasma cytokine levels

  at the end of the study, maximum 1 year

• ACE2 gene polymorphisms

  at the end of the study, maximum 1 year

Study Arms (1)

caregivers

caregivers

Other: research specific blood sample

Interventions

research specific blood sample OTHER

* one blood sample before the epidemic phase * one blood sample during epidemic phase * one blood sample after epidemic phase

caregivers

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Caregiver in Reunion island University Hospital Center who practice in a care service possibly exposed to the coronavirus

You may qualify if:

• Caregiver in Reunion island University Hospital Center
• Practicing in a care service possibly exposed to the coronavirus
• Signed Consent

You may not qualify if:

• Refusal to participate
• Already infected by Covid19

Sponsors & Collaborators

• Centre Hospitalier Universitaire de la Réunion: lead

Study Sites (2)

Centre Hospitalier Universitaire Réunion

Saint-Denis, 97400, France

Location

Centre Hospitalier Universitaire de la Réunion

Saint-Pierre, 97448, France

Location

MeSH Terms

Conditions

Severe Acute Respiratory Syndrome

Condition Hierarchy (Ancestors)

Respiratory Tract Infections; Infections; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 6, 2020
• First Posted: May 12, 2020
• Study Start: June 17, 2020
• Primary Completion: September 1, 2023
• Study Completion: September 1, 2023
• Last Updated: August 30, 2022

Record last verified: 2022-08

Data Sharing

• IPD Sharing: Will not share

Locations

FR (2)